National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Cost-utility and value of information analysis of tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma in the Irish healthcare setting. Carey N, Leahy J, Trela-Larsen L, Mc Cullagh L & Barry M (2023)   Journal of Market Access & Health Policy, 11:1, DOI: 10.1080/20016689.2023.2166375

Neoadjuvant treatment for stage III and IV cutaneous melanoma. Gorry C, McCullagh L, O’Donnell H, Barrett S, Schmitz S, Barry M, Curtin K, Beausang E, Barry R, Coyne I. Cochrane Database of Systematic Reviews 2023: Issue 1. Art. No.: CD012974. DOI: 10.1002/14651858.CD012974.pub2.

Comparative effectiveness of neutralising monoclonal antibodies in high risk COVID-19 patients: a Bayesian network meta-analysis. McConnell, D., Harte, M., Walsh, C., Murphy, D., Nichol, A., Barry, M. and Adams, R. Scientific Reports. 2022. DOI:

Tisagenlecleucel for relapsed/refractory acute lymphoblastic leukemia in the Irish healthcare setting: cost-effectiveness and value of information analysis. Carey N, Leahy J, Trela-Larsen L, McCullagh L, Barry M. International Journal of Technology Assessment in Health Care. 2022. DOI:

A text-mining tool generated title-abstract screening workload savings: performance evaluation versus single-human screening. Carey N, Harte M, Mc Cullagh L. Journal of Clinical Epidemiology. 2022. DOI:

Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements. Eichler, H., Adams, R., Andreassen, E., Arlett, P., Van de Casteele, M., Chapman, S., . . . Wenzl, M. (2021).  International Journal of Technology Assessment in Health Care, 37(1), E83. doi:10.1017/S026646232100057X

The Utility of a Rapid Review Evaluation Process to a National HTA Agency. Varley A, Tilson L, Fogarty E, McCullagh L, Barry M. PharmacoEconomics 2021. DOI: 10.1007/s40273-021-01093-8

Absence of evidence or evidence of absence – a review of the evidence for hydroxychloroquine as a potential candidate for prophylaxis against COVID-19. Cara Usher, Lea Trela-Larsen, Emer Fogarty, Aisling O’Leary, Stephen Capper, Ellen P O’Sullivan, Caitriona NiChoitir, Cathal Walsh, Michael Barry, Roisín Adams. Ann Public Health Reports 2021;5(1):160-165.DOI: 10.36959/856/513

Understanding the Challenges and Uncertainties of Seroprevalence Studies for SARS-CoV-2. McConnell D, Hickey C, Bargary N, Trela-Larsen L, Walsh C, Barry M, Adams R. Int. J. Environ. Res. Public Health 202118, 4640.

Estimating the Theoretical Cost Implications of Funding New Drugs Considered Not to Be Cost-Effective. Kennedy C,  McCullagh L,  Adams R,  Trela-Larsen L, Tilson L, Barry M, Value in Health, 2021, ISSN 1098-3015, (

Integrating clinical pharmacists within general practice: protocol for a pilot cluster randomised controlled trial. Croke A, Moriarty F,  Boland F, McCullagh L, Cardwell, K, Smith , SM,   Clynee B. BMJ Open 2021;11:e041541.

Coronavirus Disease 2019: Considerations for Health Technology Assessment From the National Centre for Pharmacoeconomics Review Group. Leahy J, Hickey C, McConnell D, Cassidy O, Trela-Larsen, L, Barry M, Tilson L, McCullagh L. Value in Health 2020.

Evaluation of the General Practice Pharmacist (GPP) intervention to optimise prescribing in Irish primary care: a non-randomised pilot study. Cardwell K, Smith S,Clyne B, McCullagh L on behalf of the General Practice Pharmacist (GPP) Study Group, et al. BMJ Open 2020; 10: e035087.

A retrospective analysis of budget impact models submitted to the National Centre for Pharmacoeconomics in Ireland. The European Journal of Health Economics.  Lamrock F,  McCullagh L, Tilson L,  Barry M. March 2020.

The Interaction between Price Negotiations and Heterogeneity: Implications for Economic Evaluations. O’Donnell H, McCullagh L, Barry M, Walsh, C. Medical Decision Making. First Published February, 2020.

Transferability of Economic Evaluations of Treatments for Advanced Melanoma. Gorry C, McCullagh L, Barry M. PharmacoEconomics (2020) 38:217–231

General practitioners’ views on malnutrition management and oral nutritional supplementation prescription in the community: a qualitative study. Dominguez Castro P, Reynolds CME, Kennelly S, Clyne B, Bury G,  Hanlon D, Murrin C, McCullagh, L, Finnigan K, Clarke S, Browne S, Perrotta C, Gibney ER, Corish CA. Clinical Nutrition ESPEN.

Analysis of Health Technology Assessments of Orphan Drugs in Ireland from 2012 to 2017.  Usher C, McCullagh L, Tilson L & Barry M. 2019 PharmacoEconomics – Open, 3, 583–589 .

Economic Evaluation of Systemic Treatments for Advanced Melanoma: A Systematic Review. Gorry C, McCullagh L, Barry M. Value in Health. 2019. 23.

To HTA or Not to HTA: Identifying the Factors Influencing the Rapid Review Outcome in Ireland. O’Donnell H, Lamrock L, Tilson L, Barry M. Value in Health 2019.

Direct oral anticoagulants uptake and an oral anticoagulant paradox. Kennedy, C. Ni Choitir, C. Clarke, S. Barry, M. Bennett, K. British Journal of Clinical Pharmacology.

Incorporating single-arm evidence into a network meta-analysis using aggregate level matching: Assessing the impact Joy Leahy, Howard Thom, Jeroen P. Jansen, Emma Gray, Aisling O’Leary, Arthur White, Cathal Walsh. Statistics in Medicine. 2019;1–19

Health Technology Assessment of Drugs in Ireland: An Analysis of Timelines. Connolly E, O’Donnell H, Lamrock F, Tilson L, Barry M.   PharmacoEconomics Open (2019).

Supporting prescribing in Irish primary care: protocol for a non-randomised pilot study of a general practice pharmacist (GPP) intervention to optimise prescribing in primary care.  Cardwell K, Clyne B, Moriarty F, Wallace E, Fahey T, Boland F, McCullagh L, Clarke S, Finnigan K, Daly M, Barry M,  Smith SM (on behalf of the General Practice Pharmacist (GPP) Study Group). Pilot and Feasibility Studies 2018 4:122.

Neoadjuvant treatment for malignant and metastatic cutaneous melanoma.  Gorry C, McCullagh L, O’Donnell H, Barrett S, Schmitz S, Barry M, Curtin K, Beausang E, Barry R, Coyne I.  Cochrane Database of Systematic Reviews 2018, Issue 3. Art. No: CD012974.

The incidence and healthcare costs of persistent postoperative pain following lumbar spine surgery in the UK: a cohort study using the Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES). Weir, S. Samnalieve, M. Tzu-Chun, K. Ni Choitir, C. Tierney, T. Taylor, R. Manca, A. Bruce, J. Cumming, D. Eldabe, S. BMJ Open 2017; 7:e017585.

The rate of persistent post-operative pain (FBSS) in revision lumbar spinal surgery. Weir, S. Samnalieve, M. Tzu-Chun, K. Ni Choitir, C. Tierney, T. Taylor, R. Manca, A. Bruce, J. Cumming, D. Eldabe, S. The Spine Journal 2017. 17(3), pp. 10. doi:

Does instrumented spinal surgery have an increased rate of persistent post-operative pain (PPP)? Weir, S. Samnalieve, M. Tzu-Chun, K. Ni Choitir, C. Tierney, T. Taylor, R. Manca, A. Bruce, J. Cumming, D. Eldabe, S. The Spine Journal 2017. 17(3), pp. 11. doi:

Acute herpes zoster and post herpetic neuralgia in primary care: a study of diagnosis, treatment and cost. Crosbie B, Lucey S, Tilson L, Domegan L, Kieran J. Eur J Clin Microbiol Infect Dis 37,627–631 (2018).

Ivacaftor for cystic fibrosis; An evaluation of real world utilisation and expenditure in the Irish Healthcare Setting. Corcoran A, Hickey N, Barry M, Usher C, McCullagh L. Irish Medical journal 2017; 110 (8):

Examining the Feasibility and Utility of Estimating Partial Expected Value of Perfect Information (via a Nonparametric Approach) as Part of the Reimbursement Decision-Making Process in Ireland: Application to Drugs for Cancer. McCullagh L, Schmitz S, Barry M, Walsh C. Pharmacoeconomics. 02/08/2017 DOI: 10.1007/s40273-017-0552-y

The cost of inpatient management of heart failure patients: a microcosting study in the Irish healthcare setting. R B Morgan, L McCullagh, M Barry, C Daly. Irish Journal of Medical Science 186293–303 (2017).

Direct costs of interferon-based and interferon-free DAA regimens for the treatment of chronic hepatitis C infection.  Gray E, O’Leary A, Kieran J, Fogarty E, Dowling T, Norris S.  Journal of Viral Hepatitis, (2016) 2016;23(9):677-86.

High mortality during direct acting antiviral therapy for hepatitis C patients with Child’s C cirrhosis:  Results from an Irish Early Access Programme.  Gray E, O’Leary A, Norris S et al on behalf of the Irish Hepatitis Outcomes Research Network. Journal of Hepatology 2016 Aug;65(2):446-8.

Do Disparities between populations in randomised controlled trails and the real world lead to differences in outcomes? Gray E, O’Leary A, Schmitz S, Norris S. In press.  Journal of Comparative Effectiveness Research, August 2016.

Cost effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients.
Gimeno-Ballester V, Mar J, O’Leary A, Adams R, San Miguel R.  Expert Review Of Gastroenterology & Hepatology 13:7, pages 699-708.

Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis.
Fogarty E, Schmitz S, Tubridy N, Walsh C, Barry M. Mult Scler Relat Disord. 2016 Sep;9:23-30.

The Pharmacoeconomic Evaluation Process in Ireland. 
McCullagh L, Barry M,  PharmacoEconomics 2016; 34(12), 1267-1276 .

Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland. Susanne Schmitz, Laura McCullagh, Roisin Adams, Cathal Walsh. PharmacoEconomics 34,925–937 (2016).

Cost-effectiveness of natriuretic peptide-based screening and collaborative care: a report from the STOP-HF (St. Vincent’s Screening To Prevent Heart Failure) Study.
Ledwidge M. T, O’Connell E, Gallagher J, Tilson L, James S, Voon V, Bermingham M, Tallon E, Watson C, O’Hanlon R, Barry M and McDonald K.  European Journal of Heart Failure, 17:672-679.

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?
Godman B, Malmström RE, Diogene E, Gray A, Jayathissa S, Timoney A, Acurcio F, Alkan A, Brzezinska A, Bucsics A, Campbell SM, Czeczot J, de Bruyn W, Eriksson I, Yusof FA, Finlayson AE, Fürst J, Garuoliene K, Guerra Júnior A, Gulbinovič J, Jan S, Joppi R, Kalaba M, Magnisson E, McCullagh L, Miikkulainen K, Ofierska-Sujkowska G, Pedersen HB, Selke G, Sermet C, Spillane S, Supian A, Truter I, Vlahović-Palčevski V, Vien LE, Vural EH, Wale J, Władysiuk M, Zeng W, Gustafsson LL. Expert Rev Clin Pharmacol. 2015 Jan;8(1):77-94.

Using the Analytic Hierarchy Process to Derive Health State Utilities From Ordinal Preference Data.
Reddy B, Kind P, Adams RC, Walsh C, Barry M. Value in Health 2014;17(7):A513. doi:/10.1016/j/jval.2014.08.1581

Health-related quality of life of patients on opiate replacement therapy.
McLaughlin J, Surah S, Synnott , Adams R, Walsh C, O’Dea S, Noone S, Keenan E, Keating S, Barry M, Bergin C, Mulcahy F, and Lyons F. Heroin Addict Relat Clin Probl 2014 (In press)

Direct and indirect economic consequences of multiple sclerosis in Ireland.
Fogarty, E; Walsh, C; McGuigan, C; Tubridy, N; Barry, M.  Applied Health Economics and Health Policy 2014;12(6):635-645.

The cost of the inpatient management of febrile neutropenia in cancer patients – a micro-costing study in the Irish healthcare setting.
C. O’Brien, E. Fogarty, C. Walsh, O. Dempsey, M. Barry, M.J. Kennedy & L. McCullagh. Eur J Cancer Care (Engl), 24: 125–132.

Natriuretic Peptide–Based Screening and Collaborative Care for Heart Failure: The STOP-HF Randomized Trial.
Ledwidge M, Gallagher J, Conlon C, Tallon E,  O’Connell E,Dawkins I, Watson C, O’Hanlon R, Bermingham M,  Patle A, MR, Murtagh G, Voon V, Tilson L, Barry M, McDonald L; Maurer B, McDonald K.  JAMA. 2013;310(1):66-74. doi:10.1001/ link

Health-related quality of life of HIV-infected intravenous drug users.
S Surah, R Adams, L Townsend, I Reynolds, JC Kinahan, S Keating, F Mulcahy, E Keenan, M Barry and F Lyons.  International Journal of STD & AIDS: Volume 24 No 11 November 2013; 867-874.

Personalizing health care: feasibility and future implications.
Godman B, Finlayson, AE, Cheema PK, Zebedin-Brandl E, Gutiérrez-Ibarluzea I, Jones J, Malmström RE, Asola E, Baumgärtel C, Bennie M, Bishop I, Bucsics A, Campbell S, Diogene E, Ferrario A, Fürst J, Garuoliene K, Gomes M, Harris K, Haycox A, Herholz H, Hviding K, Jan S, Kalaba M, Kvalheim C, Laius O, Lööv SA, Malinowska K, Martin A, McCullagh L et al.  BMC Medicine 11, 179 (2013). website link

Dabigatran – a case history demonstrating the need for comprehensive approaches to optimise the use of new drugs.
Malmstrom R, Godman B, Diogene E, Baumgaertel C, Bennie M, Bishop I, Brzezinska A, Bucsics A, Campbell S, Ferrario A, Finlayson A, Furst J, Garuoliene K, Gomes M, Gutiérrez-Ibarluzea I, Haycox A, Hviding K, Herholz H, Hoffmann M, Jan S, Jones J, Joppi R, Kalaba M, Kvalheim C, Laius O, Langner I, Lonsdale J, Loov SA, Malinowska K, McCullagh L et al.  Front. Pharmacol. | doi: 10.3389/fphar.2013.00039.  May 2013; Volume 4, Article 39. Available at Website Link

Using resource modelling to inform decision making and service planning:  the case of colorectal cancer screening in Ireland.
Sharpe L, Tilson L, Whyte S, O Ceilleachair A, Walsh C, Usher C, Tappenden P, Chilcott J, Staines A, Barry M, Comber H.  BMC Health Services Research 2013, 13:105 doi:10.1186/1472-6963-13-105 Website Link

Incorporating data from various trial designs into a mixed treatment comparison model.
Schmitz S, Adams R, Walsh C
. Statistics in Medicine.  Article first published online: 25 FEB 2013.

Relating Health-related Quality of Life to Disability Progression in Multiple Sclerosis using the Five-level EQ-5D.
Fogarty E, Walsh C, Adams R
, McGuigan C, Barry M, Tubridy N.  Multiple Sclerosis 2013;19(9):1190-1196. website link